Foot and mouth disease virus vaccines

Rodrı́guez, Luis L.; Grubman, Marvin J.

doi:10.1016/j.vaccine.2009.08.039

Cited by 169 publications

(162 citation statements)

References 70 publications

Supporting

Mentioning

159

Contrasting

Unclassified

Order By: Relevance

“…Vaccines are formulated with specific strains depending on the geographical area of interest, and they require 5 to 7 days to provide effective protection (2,37,38). Here, we show that in swine, administration of Ad5-poIRF7/3(5D) has potential as an effective biotherapeutic strategy against FMD as early as 24 h posttreatment.…”

Section: Discussionmentioning

confidence: 88%

Constitutively Active IRF7/IRF3 Fusion Protein Completely Protects Swine against Foot-and-Mouth Disease

Ramírez-Carvajal¹,

Segundo

Ramírez-Medina³

et al. 2016

J Virol

View full text Add to dashboard Cite

Foot-and-mouth disease (FMD) remains one of the most devastating livestock diseases around the world. Several serotype-specific vaccine formulations exist, but they require about 5 to 7 days to induce protective immunity. Our previous studies have shown that a constitutively active fusion protein of porcine interferon (IFN) regulatory factors (IRF) 7 and 3 [IRF7/3(5D)] strongly induced type I IFN and antiviral genes in vitro and prevented mortality in an FMD mouse model when delivered with a replication-defective adenoviral vector [Ad5-poIRF7/3(5D)]. Here, we demonstrate that pigs treated with 10 8 , 10 9 , or 10 10 PFU of Ad5-poIRF7/3(5D) 24 h before FMDV challenge were fully protected from FMD clinical signs and did not develop viremia, virus shedding or antibodies against FMDV nonstructural proteins. Pigs treated with Ad5-poIRF7/3(5D) had higher levels of IFN and antiviral activity in serum, and upregulated expression of several IFN-stimulated genes in peripheral blood mononuclear cells, compared to pigs treated with Ad5-Blue vector control. Importantly, treatment of porcine cultured cells with Ad5-poIRF7/3(5D) inhibited the replication of all 7 FMDV serotypes. In vitro experiments using cultured embryonic fibroblasts derived from IFN receptor knockout mice suggested that the antiviral response induced by Ad5-poIRF7/3(5D) was dependent on type I and III IFN pathways; however, experiments with mice demonstrated that a functional type I IFN pathway mediates Ad5-poIRF7/3(5D) protection conferred in vivo. Our studies demonstrate that inoculation with Ad5-poIRF7/3(5D) completely protects swine against FMD by inducing a strong type I IFN response and highlights its potential application to rapidly and effectively prevent FMDV replication and dissemination. IMPORTANCEFoot-and-mouth disease virus (FMDV) causes a fast-spreading disease that affects farm animals, with economically and socially devastating consequences. Our study shows that inoculation with a constitutively active transcription factor, namely, a fusion protein of porcine interferon (IFN) regulatory factors (IRF) 7 and 3 delivered by an adenovirus vector [Ad5-poIRF7/3(5D)], is a new effective treatment to prevent FMD in swine. Animals pretreated with Ad5-poIRF7/3(5D) 1 day before being exposed to FMDV were completely protected from viral replication and clinical disease. It is noteworthy that the doses of Ad5-poIRF7/ 3(5D) required for protection are lower than those previously reported for similar approaches using Ad5 vectors delivering type I, II, or III IFN, suggesting that this novel strategy would be economically appealing to counteract FMD. Our results also indicate that a dynamic interplay among different components of pigs' innate immune defenses allows potent antiviral effects after Ad5-poIF7/3(5D) administration. F oot-and-mouth disease virus (FMDV) causes an economically, socially devastating, fast-spreading disease that affects a wide range of farm and wild cloven-hooved animals (1). The existence of seven serotypes (A, Asia1, C, O, a...

show abstract

Section: Discussionmentioning

confidence: 88%

Constitutively Active IRF7/IRF3 Fusion Protein Completely Protects Swine against Foot-and-Mouth Disease

Ramírez-Carvajal¹,

Segundo

Ramírez-Medina³

et al. 2016

J Virol

View full text Add to dashboard Cite

show abstract

“…Adenoviruses are showing substantial promise as vehicles for antigen delivery in the development many veterinary vaccines. Adenoviruses are showing substantial promise as vehicles for antigen delivery for a number of vaccines currently being developed (Rodriguez and Grubman, 2009). …”

Section: Introductionmentioning

confidence: 99%

Review on Adeno Virus; As a Vaccine Vehicle

2017

ARC Journal of Animal and Veterinary Sciences

View full text Add to dashboard Cite

“…1 Currently available FMD vaccines are mainly based on inactivated viral antigens formulated with various proprietary adjuvants. 2 Despite tremendous progress in FMD vaccine production in recent years, the use of conventional and chemically inactivated FMD virus (FMDV) vaccines is associated with a number of concerns and deficiencies: [3][4][5] (1) large doses are required and induce only a short duration of immunity and a limited spectrum of antiviral immune responses; (2) unless highly purified, the vaccines do not allow differentiation between infected and vaccinated animals; (3) animals vaccinated with the current vaccines are generally protected against disease and induce serum immunoglobulin (Ig)G antibodies but have low stimulation of secretory IgA (sIgA) at respiratory mucosal sites and show sporadic CD8 + cytotoxic T lymphocytes; and (4) the current vaccines requires 7-14 days to induce protection. 6 The time for protection to develop leaves an immunity gap, a window of susceptibility prior to induction of the adaptive immune response in which vaccinated animals are still susceptible to disease; (5) protection is short-lived, often requiring frequent revaccination, and manipulation of large amounts of virulent virus could result in viral dissemination; (6) vaccination does not prevent colonization of the upper respiratory tract and development of the carrier state.…”

Section: Introductionmentioning

confidence: 99%

Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles

Pan¹,

Zhang²,

Lv³

et al. 2014

IJN

View full text Add to dashboard Cite

The aim of this study was to enhance specific mucosal, systemic, and cell-mediated immunity and to induce earlier onset of protection against direct-contact challenge in cattle by intranasal delivery of a nanoparticle-based nasal vaccine against type A foot-and-mouth disease (FMD). In this study, two kinds of nanoparticle-based nasal vaccines against type A FMD were designed: (1) chitosan-coated poly(lactic-co-glycolic acid) (PLGA) loaded with plasmid DNA (Chi-PLGA-DNA) and (2) chitosan-trehalose and inactivated foot-and-mouth disease virus (FMDV) (Chi-Tre-Inactivated). Cattle were immunized by an intranasal route with nanoparticles and then challenged for 48 hours by direct contact with two infected donor cattle per pen. Donors were inoculated intradermally in the tongue 48 hours before challenge, with 0.2 mL cattle-passaged FMDV. Serological and mucosal antibody responses were evaluated, and virus excretion and the number of contact infections were quantified. FMDV-specific secretory immunoglobulin (Ig)A (sIgA) antibodies in nasal washes were initially detected at 4 days postvaccination (dpv) with two kinds of nanoparticles. The highest levels of sIgA expression were observed in nasal washes, at 10 dpv, from animals with Chi-PLGA-DNA nanoparticles, followed by animals immunized once by intranasal route with a double dose of Chi-Tre-Inactivated nanoparticles and animals immunized by intranasal route three times with Chi-Tre-Inactivated nanoparticles ( P <0.05). FMDV-specific IgA antibodies in serum showed a similar pattern. All animals immunized by intranasal route developed low levels of detectable IgG in serum at 10 dpv. Following stimulation with FMDV, the highest levels of proliferation were observed in splenocytes harvested from Chi-PLGA-DNA-immunized animals, followed by proliferation of cells harvested from Chi-Tre-Inactivated nanoparticle-immunized animals ( P <0.05). Higher protection rates were associated with the highest sIgA antibody responses induced in the Chi-PLGA-DNA nanoparticle-immunized group. Only one animal was clinically affected with mild signs after 7 days of contact challenge, after a delay of 2–3 days compared with the clinically affected negative-control group. Of the five animals directly challenged that were vaccinated by intranasal route with a double dose of Chi-Tre-Inactivated, four were clinically infected; however, the degree of severity of disease in this group was lower than in control cattle. The number of viral RNA copies in nasal swabs from the vaccinated, severely infected group was significantly higher than in swabs from the vaccinated, clinically protected group. These data suggested that intranasal delivery of Chi-PLGA-DNA nanoparticles resulted in higher levels of mucosal, systemic, and cell-mediated immunity than did of Chi-Tre-Inactivated nanoparticles. In conclusion, although intranasal delivery with FMDV antigen mediated by nanoparticles did not provide complete clinical protection, it reduced disease severity and...

show abstract

Foot and mouth disease virus vaccines

Cited by 169 publications

References 70 publications

Constitutively Active IRF7/IRF3 Fusion Protein Completely Protects Swine against Foot-and-Mouth Disease

Constitutively Active IRF7/IRF3 Fusion Protein Completely Protects Swine against Foot-and-Mouth Disease

Review on Adeno Virus; As a Vaccine Vehicle

Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles

Contact Info

Product

Resources

About